Coreg (carvedilol) for MI patients with decreased left ventricular function

July 2003

Glaxo is now promoting Coreg (carvedilol) for MI patients with decreased left ventricular function.

Coreg is the first beta-blocker APPROVED specifically for these patients. It reduces mortality by about 23%.

Some reps will say that Coreg is better than the older beta-blockers...metoprolol, atenolol, propranolol, etc.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote